Post Marketing evaluation of Anti Snake Venom (ASV) administered as a standard treatment for snakebite. Experience from western India
DOI:
https://doi.org/10.37506/9w4gpf62Keywords:
Anti-Snake Venom Serum, Adverse events, Envenomation, Hemotoxic, NeurotoxicAbstract
Aim: To study the safety profile and effectiveness of Anti Snake venom (ASV) in western India
Methods: This retrospective study gathered safety, epidemiological and clinical data on 157 snake bite patients admitted at Shri Sainath Hospital, in Dharampur, Gujarat, from July 2022 to February 2023.
Results: Majority of the bites occurred between August and November. There were 88 males between 5 and 70 yrs. (mean 39.14 yrs.), 69 females between 2 and 70 years (mean 40.32 yrs.). 6 of these were children ranging from 2 to 12 years.134 were agricultural labourers.
120 cases were analysable. 17 had neurotoxicity and 103 had haemotoxicity. Mean (SD) number of vials used was 10.1(6.2), time to discontinue ASV was 3.0(5.2) hours, and duration of hospital stay was 4.5(2.6) days. Patients bitten by saw scaled vipers were discharged early. In Russel’s Viper bites, number of vials used, was higher if the bite to needle time was less than 6 hours
9 patients suffered 24 adverse events, with two possible cases of anaphylaxis. One case had urticaria, itching and tachycardia as a triad. The remaining were isolated events of mild urticaria, itching, tachycardia, hypotension, cough, rigor.
Conclusion: All cases were successfully managed with no fatalities or severe comorbidities. Adverse events were reported in 5.7% cases. Mean of 10.1 vials were needed for control of envenomation, a number much less that national guidelines. The ASV brand used was well tolerated. Patients who were brought late suffered more renal complications
References
Alirol E, Sharma SK, Bawaskar HS, Kuch U, Chappuis F (2010) Snake Bite in South Asia: A Review. PLoS Negl Trop Dis 4(1): e603. doi:10.1371/ journal.pntd.0000603
Guidelines for management of Snakebites, New Delhi, WHO Regional Office for South East Asia,2016
Kalyan kumar B, Nanda S.S, Venkateshwarlu P, Kiran kumar Y, Jadhav R.T. Anti Snake Venom Serum (ASV) International Journal on Pharmaceutical and Biomedical Research (IJPBR)2010; 1:76-89
Sharma N, Chauhan S, Faruqi S, Bhat P, Varma S, Snake envenomation in a north Indian hospital, Emerg Med J 2005;22:118–120. doi: 10.1136/emj.2003.008458
Brown SGA, Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004;114:371-6
Seneviratne SL, Opanayaka CJ, Ratnayake NS et al. Use of antivenom serum in snake bite: a prospective study of hospital practice in the Gampaha district. Ceylon Med J. 2000; 45:65-8
Hui Wen Fan, Luiz F Marcopito, João Luiz C Cardoso et al Sequential randomised and doubleblind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites. BMJ 1999; 318:1451–2
Amin MR, Mamun SMH, Rashid R et al. Antisnake Venom: Use and adverse reactions in a snake bite study clinic in Bangladesh. J. Venom. Anim. Toxins incl. Trop. Dis. 2008; 14:660-672
Deshmukh VS, Motghare VM, Gajbhiye D et al.Study on acute adverse reactions of Anti Snake Venom in a rural tertiary care hospital. 45Asian J Pharm Clin Res, 2014;7: 13-15
Deshpande RP, Motghare VM, Padwal SL, et al, Adverse drug reaction profile of anti-snake venom in a rural tertiary care teaching hospital. Journal of Young Pharmacists 2013; 5:41
Mathivani M, Parameswari R, Sarojini R,Geetha K, and Gowrithilagam T . Pattern of Use and Adverse Reactions to Antisnake Venom in Haemotoxic Snake Bite. RJPBCS 2013: 4, 100
JC Menon, JK Joseph, MP Jose, BL Dhananjaya, OV Oommen, Clinical Profile and Laboratory Parameters in 1051 Victims of Snakebite from a Single Centre in Kerala, South India; Journal of Association of Physicians of India,2016;64:22
Ramesh J, Sovani VB, Baskeran R, Sivasankari N, Arun R, Efficacy and Safety of Anti Snake Venom, used as per National Guidelines, at a Tertiary Care Centre in Puducherry, Indian J of Pub. Health Res. and Dev. 2020; 11:220
Sudeep Kumar , Sovani VB , Bhoge DP ,Postmarketing safety and usage study of anti-snake venom in a tertiary hospital in Talegaon, Maharashtra, Global J of Med. And Pub. Health( GJMPH), 2019; 8:4,1
Standard Treatment Guidelines, Management of Snakebites. Ministry of Health and Family Welfare. January 2016
N Suchithra, J M Pappachan, P Sujathan. Snakebite envenoming in Kerala, South India: clinical profile and factors involved in adverse outcomes Emerg Med J 2008;25:200–204
Suchaya Sanhajariya , Stephen B. Duffull , Geoffrey K. Isbister, Pharmacokinetics of Snake Venom, Toxins 2018, 10: 73; doi:10.3390/toxins10020073
Blessmann J, Kreuels B Urgent administration of antivenom following proven krait bites in Southeast Asia irrespective of neurotoxic symptoms. PLoS Negl Trop Dis (2024) 18(4): e0012079.
https://doi.org/10.1371/journal.pntd.0012079
Target product profilesfor animal plasma-derived antivenoms for treatment of snakebite envenoming in south Asia .WHO draft for public consultation 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Dhirubhai C Patel, V B Sovani, Patel N J
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.